[Newer antipsychotics for maintenance treatment of bipolar disorder]
The Swedish Council on Health Technology Assessment (SBU)
Record ID 32013000343
Swedish
Authors' recommendations:
In the long-term:
As there are no studies of more than two years' duration, it is not possible to assess the long-term benefits and risks of SGA for maintenance treatment of bipolar disorder.
In the short-term:
Bipolar disorder type I -
For patients with bipolar disorder type I who have responded to aripiprazole, quetiapine or ziprasidone as adjunct to mood stabilisers in the manic acute phase, the risk of relapse is reduced when these drugs are used during maintenance.
There is insufficient quality of studies in order to evaluate the effects of maintenance treatment using olanzapine and risperidone.
In some patients, quetiapine could be an alternative to lithium for reducing the risks of relapse and treatment discontinuation. While the risk of serious side effects must be considered, to date no long term studies are available.
Weight gain is frequently associated with all of the SGA investigated. Aripiprazole causes slightly more tremors and tingling in the legs than mood stabilisers. Olanzapine and quetiapine are associated with more daytime drowsiness and less insomnia than mood stabilisers. It is a requirement that side effects are reported to the Medical Products Agency and should be followed up in quality registers.
Drugs which prevent relapses have the potential to redeem much of their cost by reducing the healthcare costs associated with relapses. Fewer relapses improve quality of life and survival.
Bipolar disorder type II
In the absence of studies, no conclusions can be drawn about the effect of SGA as maintenance treatment for bipolar disorder type II.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.sbu.se/201502E
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Sweden
MeSH Terms
- Antipsychotic Agents
Contact
Organisation Name:
Swedish Agency for Health Technology Assessment and Assessment of Social Services
Contact Address:
P.O. Box 3657, SE-103 59 Stockholm, Sweden. Tel: +46 8 4123200, Fax: +46 8 4113260
Contact Name:
registrator@sbu.se
Contact Email:
registrator@sbu.se
Copyright:
The Swedish Council on Health Technology Assessment (SBU)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.